| | | |   | | | | By Ed Silverman Gene J. Puskar/AP CVS ignored red flags that were signs that “numerous controlled substances… were not issued for a legitimate medical purpose.” Read More | | By Amar Kelkar and Julie Kanter and Payal Desai Michael Conroy/AP Creating comprehensive care centers for people with sickle cell disease is needed to address this long-overlooked life-threatening condition. Read More | | By Mario Aguilar Adobe Medicare's hospital at home program may soon be extended. It will need to prove it can deliver good outcomes and be financially viable. Read More | | Sponsored Insight by Janssen Research & Development, LLC. Precision medicine for major depressive disorder has the potential to address critical, unmet needs Nearly 70% of people with major depressive disorder (MDD) treated with antidepressant drugs from the selective serotonin reuptake inhibitor class experience residual symptoms like anxiety, impaired cognition, insomnia, fatigue, and anhedonia. Fortunately, neuroscience is entering a new era of precision medicine based on scientific and digital advances. Scientists are evaluating how to recognize illness subtypes and predict which people with MDD will respond to a particular treatment. Read the article here. | |
No comments